Gold prices steady ahead of Fed decision; weekly weakness noted
SCOTTSDALE, Ariz. - The Joint Corp. (NASDAQ: JYNT), a leading national provider of chiropractic care, has announced a stock repurchase program where it may buy back up to $5 million of its outstanding common stock starting in August 2025. Currently trading at $11.11 with a market capitalization of $170 million, InvestingPro analysis suggests the stock is slightly undervalued. The initiative, as stated by CEO Sanjiv Razdan, underscores the company’s confidence in its long-term strategy and commitment to delivering shareholder value.
The repurchase program, which does not require the company to purchase any specific number of shares, is set to conclude by June 3, 2027. The Joint Corp. will conduct the buybacks through open market transactions, private deals, or other methods, depending on market conditions and other factors. Analyst targets for the stock range from $10.50 to $20.00, reflecting varied opinions on the company’s future prospects.
The Joint Corp., headquartered in Scottsdale, Arizona, has revolutionized the chiropractic industry with its retail healthcare business model since 2010. Operating over 950 locations nationwide, it has facilitated more than 14 million patient visits per year. The company maintains a robust gross profit margin of 77.7% and holds more cash than debt on its balance sheet. According to InvestingPro, which offers comprehensive analysis of over 1,400 US stocks, analysts expect net income growth this year despite recent challenges. The company has been recognized for its growth and franchise model, earning spots on various prestigious lists, including Franchise Times’ Top 400 and Entrepreneur’s Franchise 500.
This press release contains forward-looking statements regarding the company’s expectations about the stock buyback’s reflection of the board’s confidence in the company’s future financial performance and valuation. However, it is important to note that these statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those projected.
The Joint Corp.’s business structure involves both franchising and operating clinics, providing management services to affiliated professional chiropractic practices in select states. The company’s innovative approach merges healthcare with retail, aiming to make quality care both convenient and affordable without the need for insurance.
The information disclosed in this article is based on a press release statement from The Joint Corp. and does not include speculative content or endorsements of claims. The focus remains on presenting the key facts about the stock repurchase program and the company’s current market position. For deeper insights into The Joint Corp.’s financial health, growth prospects, and detailed valuation metrics, investors can access the full Pro Research Report available on InvestingPro.
In other recent news, The Joint Corp. reported its Q1 2025 earnings, showcasing a notable earnings per share (EPS) achievement of $0.05, surpassing the anticipated $0.01. However, the company faced a revenue shortfall, reporting $13.1 million compared to the expected $27.5 million. Despite the revenue miss, the company saw a 7% increase in revenue from continuing operations year-over-year. In terms of strategic changes, The Joint Corp. announced the appointment of Sandi Karrmann and Christopher M. Grandpre to its Board of Directors, aiming to support growth in key areas such as clinic openings and system-wide sales. The company continues its transition towards becoming a pure play franchisor, with plans to open 30 to 40 new franchise clinics in 2025. Additionally, The Joint Corp. is enhancing its digital marketing and launching a new mobile app to improve patient engagement. Analyst feedback, including insights from ROTH Capital Partners, suggests that the company’s strategic initiatives and pricing adjustments could have a significant impact on sales.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.